Business Context and Reporting Period
Aptevo Therapeutics Inc. filed this Form 8-K on March 7, 2019, to report the entry into an underwriting agreement with Piper Jaffray & Co. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $20.2 million expected after deducting underwriting discounts, commissions, and estimated offering expenses.
- Securities Issued:
- 19,850,000 shares of Common Stock.
- Warrants to purchase up to 22,000,000 shares of Common Stock.
- Pre-funded warrants to purchase up to 2,150,000 shares of Common Stock.
- Offering Prices:
- Combined price for one Share and one Warrant: $1.00.
- Combined price for one Pre-Funded Warrant and one Warrant: $0.99.
- Warrant Terms:
- Standard Warrants: Initial exercise price of $1.30 per share; expire five years from issuance.
- Pre-Funded Warrants: Initial exercise price of $0.01 per share; expire ten years from issuance.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels as this is a current report regarding a capital raise rather than a periodic financial statement.
Material Changes
The primary material change is the execution of the underwriting agreement to raise capital. The company will issue new equity and warrant instruments, increasing its outstanding share count and potential future dilution upon exercise. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
- Adjustments: Exercise prices and share counts are subject to adjustment for stock dividends, splits, reclassifications, or combinations.
- Fundamental Transactions: In the event of a merger, consolidation, or acquisition of more than 50% of voting stock, the successor entity must assume obligations to warrant holders. If the successor is not a publicly traded corporation assuming the warrants, holders have the right to require a cash repurchase equal to the Black-Scholes value of the unexercised portion.
- Legal Opinions: The legality of the issuance is supported by an opinion from Cooley LLP.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $20.2 million.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or additional covenants.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Monitor the exercise activity of the warrants and pre-funded warrants over the next 5 to 10 years.